US House panel adopts 12-year exclusivity for biologicals
This article was originally published in Scrip
Executive Summary
The US House energy and commerce committee on July 31st overwhelmingly adopted a biosimilars amendment to a massive healthcare reform bill that would give innovative biologicals 12 years of data exclusivity. The measure also allows for a six-month exclusivity extension in exchange for conducting paediatric studies.